The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

被引：789

作者：

Kotschy, Andras ^{[1
]}

Szlavik, Zoltan ^{[1
]}

Murray, James ^{[2
]}

Davidson, James ^{[2
]}

Maragno, Ana Leticia ^{[3
]}

Le Toumelin-Braizat, Gaetane ^{[3
]}

Chanrion, Maia ^{[3
]}

Kelly, Gemma L. ^{[4
,5
]}

Gong, Jia-Nan ^{[4
,5
]}

Moujalled, Donia M. ^{[6
]}

Bruno, Alain ^{[3
]}

Sekei, Marton C. ^{[1
]}

Paczal, Attila ^{[1
]}

Szabo, Zoltan B. ^{[1
]}

Sipos, Szabolcs ^{[1
]}

Radics, Gabor ^{[1
]}

Proszenyak, Agnes ^{[1
]}

Balint, Balazs ^{[1
]}

Ondi, Levente ^{[1
]}

Blasko, Gabor ^{[1
]}

Robertson, Alan ^{[2
]}

Surgenor, Allan ^{[2
]}

Dokurno, Pawel ^{[2
]}

Chen, Ijen ^{[2
]}

Matassova, Natalia ^{[2
]}

Smith, Julia ^{[2
]}

Pedder, Christopher ^{[2
]}

Graham, Christopher ^{[2
]}

Studeny, Aurelie ^{[3
]}

Lysiak-Auvity, Gaelle ^{[3
]}

Girard, Anne-Marie ^{[3
]}

Grave, Fabienne ^{[3
]}

Segal, David ^{[4
,5
]}

Riffkin, Chris D. ^{[4
,5
]}

Pomilio, Giovanna ^{[6
]}

Galbraith, Laura C. A. ^{[4
,5
]}

Aubrey, Brandon J. ^{[4
,5
,7
]}

Brennan, Margs S. ^{[4
,5
]}

Herold, Marco J. ^{[4
,5
]}

Chang, Catherine ^{[4
,5
]}

Guasconi, Ghislaine ^{[3
]}

Auquil, Nicolas C. ^{[3
]}

Melchiore, Fabien ^{[8
]}

Guigal-Stephan, Nolwen ^{[8
]}

Lockhart, Brian ^{[8
]}

Colland, Frederic ^{[3
]}

Hickman, John A. ^{[3
]}

Roberts, Andrew W. ^{[4
,5
,9
]}

Huang, David C. S. ^{[4
,5
]}

Wei, Andrew H. ^{[6
,10
]}

机构：

[1] Servier Res Inst Med Chem, H-1031 Budapest, Hungary

[2] Vernalis R&D Ltd, Cambridge CB21 6GB, England

[3] Inst Rech Servier Oncol, R&D Unit, F-78290 Croissy Sur Seine, France

[4] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3052, Australia

[5] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia

[6] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia

[7] Royal Melbourne Hosp, Victorian Comprehens Canc Ctr, Dept Clin Haematol & Bone Marrow Transplantat, Melbourne, Vic 3050, Australia

[8] Inst Rech Servier, Biomarker Res Div, F-78290 Croissy Sur Seine, France

[9] Univ Melbourne, Fac Med, Melbourne, Vic 3010, Australia

[10] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic 3004, Australia

[11] Univ Melbourne, Dept Pharmacol & Pharmaceut, Melbourne, Vic 3010, Australia

来源：

NATURE | 2016年 / 538卷 / 7626期

基金：

英国医学研究理事会;

关键词：

ANTI-APOPTOTIC MCL-1; BCL-XL; MULTIPLE-MYELOMA; HIGH-AFFINITY; TUMOR-CELLS; SURVIVAL; PROTEIN; COMBINATION; DEPENDENCY; NAVITOCLAX;

D O I：

10.1038/nature19830

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

引用

页码：477 / +

页数：20

共 50 条

[21] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Nabanita Mukherjee
Jenette Skees
Kaleb J. Todd
Drake A. West
Karoline A. Lambert
William A. Robinson
Carol M. Amato
Kasey L. Couts
Robert Van Gulick
Morgan MacBeth
Kelsey Nassar
Aik-Choon Tan
Zili Zhai
Mayumi Fujita
Stacey M. Bagby
Chiara R. Dart
James R. Lambert
David A. Norris
Yiqun G. Shellman
Cell Death & Disease, 11
[22] Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Prukova, Dana
Andera, Ladislav
Nahacka, Zuzana
Karolova, Jana
Svaton, Michael
Klanova, Magdalena
Havranek, Ondrej
Soukup, Jan
Svobodova, Karla
Zemanova, Zuzana
Tuskova, Diana
Pokorna, Eva
Helman, Karel
Forsterova, Kristina
Pacheco-Blanco, Mariana
Vockova, Petra
Berkova, Adela
Fronkova, Eva
Trneny, Marek
Klener, Pavel
CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4455 - 4465
[23] Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Merino, Delphine
Whittle, James R.
Vaillant, Francois
Serrano, Antonin
Gong, Jia-Nan
Giner, Goknur
Maragno, Ana Leticia
Chanrion, Maia
Schneider, Emilie
Pal, Bhupinder
Li, Xiang
Dewson, Grant
Grasel, Julius
Liu, Kevin
Lalaoui, Najoua
Segal, David
Herold, Marco J.
Huang, David C. S.
Smyth, Gordon K.
Geneste, Olivier
Lessene, Guillaume
Visvader, Jane E.
Lindeman, Geoffrey J.
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (401)
[24] Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845
Fruman, David
Juarez, Dennis
Diep, Grace
Nguyen, Falisha
Gupta, Vikas A.
Boise, Lawrence H.
BLOOD, 2019, 134
[25] Shotgun Lipidomics Elucidates the Lipidome Alterations of the Mcl-1 Inhibitor S63845 in AML Cell Lines with a Focus on Sphingolipids
Yandim, Melis Kartal
Bilgin, Mesut
EXPERIMED, 2022, 12 (03): : 209 - 214
[26] AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Caenepeel, Sean
Brown, Sean P.
Belmontes, Brian
Moody, Gordon
Keegan, Kathleen S.
Chui, Danny
Whittington, Douglas A.
Huang, Xin
Poppe, Leszek
Cheng, Alan C.
Cardozom, Mario
Houze, Jonathan
Li, Yunxiao
Lucas, Brian
Paras, Nick A.
Wang, Xianghong
Taygerly, Joshua P.
Vimolratana, Marc
Zancanella, Manuel
Zhu, Liusheng
Cajulis, Elaina
Osgood, Tao
Sun, Jan
Damon, Leah
Egan, Regina K.
Greninger, Patricia
McClanaghan, Joseph D.
Gong, Jianan
Moujalled, Donia
Pomilio, Giovanna
Beltran, Pedro
Benes, Cyril H.
Roberts, Andrew W.
Huang, David C.
Wei, Andrew
Canon, Jude
Coxon, Angela
Hughes, Paul E.
CANCER DISCOVERY, 2018, 8 (12) : 1582 - 1597
[27] Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
Seyfried, Felix
Stirnweiss, Felix
Koehrer, Stefan
Debatin, Klaus-Michael
Meyer, Lueder Hinrich
BLOOD, 2018, 132
[28] Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3-ITD Mutated Acute Myeloid Leukemia (AML)
Skwarska, Anna
Panis, Paul
Zhang, Qi
Herbrich, Shelley
Kurvilla, Vinitha M.
Baran, Natalia
Halilovic, Ensar
Ruvolo, Peter
Ruvolo, Vivian
Morris, Erick
Wei, Andrew
Moujalled, Donia
Derreal, Alix
Banquet, Sebastien
Andreeff, Michael
Konopleva, Marina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S221
[29] S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver
Letai, Anthony
CANCER CELL, 2016, 30 (06) : 834 - 835
[30] Synergistic Interaction between the MCL-1-Specific Inhibitor S63845 and Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
Seyfried, Felix
Stirnweiss, Felix
Koehrer, Stefan
Debatin, Klaus-Michael
Meyer, Lueder Hinrich
CELL DEATH DISCOVERY, 2019, 5

← 1 2 3 4 5 →